Items in cart [0] Questions? Call 888-624-8373

HARDBACK + PDF your price: $50.50 add to cart HARDBACK list:$42.95 Web:$38.66 add to cart PDF BOOK your price: $33.00 add to cart PDF CHAPTERS your price: $3.90 select Rights & Permissions Free Resources PDF EXECUTIVE SUMMARY Display this book on your site! Related Titles Pathways of Addiction: Opportunities in Drug Abuse Research Marijuana As Medicine?: The Science Beyond the Controversy Other Related Titles Marijuana and Medicine: Assessing the Science Base (1999) Institute of Medicine (IOM) Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Page 223   E-mail  Facebook  Digg  Stumble  Twitter More The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Page 223 APPENDIXES Page 223 Front Matter (R1-R18) Executive Summary (1-12) 1 Introduction (13-32) 2 Cannabinoids and Animal Physiology (33-82) 3 First, Do No Harm: Consequences of Marijuana Use and Abuse (83-136) 4 The Medical Value of Marijuana and Related Substances (137-192) 5 Development of Cannabinoid Drugs (193-222) Appendix A Individuals and Organizations That Spoke or Wrote to the Institute of Medicine About Marijuana and Medicine (223-231) Appendix B Workshop Agendas (232-239) Appendix C Scheduling Definitions (240-241) Appendix D Statement of Task (242-243) Appendix E Recommendations Made in Recent Reports on the Medical Use of Marijuana (244-255) Appendix F Rescheduling Criteria (256-258) Index (259-267)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 223
Page 223 APPENDIXES

OCR for page 224
which generally involves three phases (see figure 5.1). The three stages of clinical testing are usually the most time-consuming phases of drug development, lasting five years on average.22 The actual time depends on the complexity of the drug, availability of patients, duration of use, difficulty of measuring clinical end points, therapeutic class, and indication (the disease or condition for which the drug has purported benefits).3~ s.4

OCR for page 225
Page 225 Appendix A Individuals and Organizations That Spoke or Wrote to the Institute of Medicine About Marijuana and Medicine Donald I. Abrams University of California at San Francisco Jill Aguilera Colorado Federation of Parents William F. Alden D.A.R.E. America Roger D. Anderson Anderson Clinical Research M. Douglas Anglin UCLA Drug Abuse Research Center Dave Baleria Jackson County Sheriff's Office Joe Barker Frank Bartosic Minister of Universal Life Church Dana Beal Cures Not Wars J. Bellam Center for Drug Information Sandra S. Bennett Northwest Center for Health and Safety Anna T. Boyce California Senior Legislature (Prop 215) William Britt Richard Brookhiser National Revietw Ronald Brooks California Narcotic Officers Association Bonnie Broussard L.A. Takes a Stand, Inc.

OCR for page 226
Page 226 Al Byrne Patients Out of Time Marvin Edward Chavez, Sr. O.C. Patient-Doctor-Nurse Support Group Cannabis Co-Op Steven Childers Bowman Gray School of Medicine Wake Forest University Barb Christensen Prevention Partners Gale Cincotta National People's Action Carol Coburn Prevention Partners Chris Conrad Author of Hemp for Health Paul Consroe University of Arizona J. Richard Crout Private Consultant Judy Cushing Oregon Partnership, National Family Partnership John De Miranda Peninsula Health Concepts Mahendra Dedhiya Roxane Laboratories, Inc. Robert Deitch Cannabis Freedom Fund Philip Diaz Physicians for Prevention Stephen L. Dilts American Academy of Addiction Psychiatry Rick Doblin MAPS and Kennedy School of Government Del Dolton Barbara Douglass Drug-Free Youth-USA Robert Dudley UNIMED Victoria Duran National Parents and Teachers Association David Edwards Edward Ehman Certified Prevention Specialist Mahmoud ElSohly University of Mississippi Mouncey Ferguson Howard L. Fields University of California at San Francisco Jody Fitt Richard W. Foltin Columbia University

OCR for page 227
Page 227 Etienne Fontan Cannabis Alliance of Veterans, 1st CAV Meg Foster Phyllis Gardner ALZA Corporation Charles V. Giannasio American Academy of Addiction Psychiatry Dale Gieringer California NORML, Friends of 215 Mark Gold University of Florida Brain Institute Richard Gralla OCHSNER Cancer Institute Linda Hall Pride, Omaha, Inc. Margaret Haney Columbia University Ann Hansen Michigan Communities in Action for Drug-Free Youth Jim Hardin Terry Hensley Drug-Free America Foundation Kimberly Hessel American Cancer Society and Muscatine General Hospital Michele Hodak National Education Association Leo Hollister Harris County Psychiatric Center Jennifer Hudson Oregonians Against Dangerous Drugs Paul Isford Becki Jelinek Family Service/South Omaha Counseling Jeffery Jones Oakland Cannabis Buyers' Cooperative Linda R. Wolf Jones Therapeutic Communities of America Norbert E. Kaminski Michigan State University Robert Kampia Marijuana Policy Project Paul L. Kaufman University of Wisconsin Medical School Andrew Kinnon Thomas Klein University of South Florida College of Medicine Audra Koerber Orange County Patient, Doctor, Nurse Support Group

OCR for page 228
Page 228 Ellen Komp San Luis Obispo Citizens for Medical Marijuana George Koob Scripps Research Institute Thomas R. Kosten American Academy of Addiction Psychiatry Donald Kotler St. Luke's-Roosevelt Hospital Michael Krawitz Disabled American Veterans, American Legion Kiyoshi Kuromiya Critical Path AIDS Project Karin Kyles Connecticut Communities for Drug-Free Youth, Inc. Eric Larson University of Washington Medical Center Linda B. Ledger O. J. Federation for Drug-Free Communities Carla Lowe Ray Lozano C.A.D.F.Y. Patrick Magee Orange County Hemp Council Robert L. Maginnis Family Research Council Billy R. Martin Virginia Commonwealth University Mary Lynn Mathre Patients Out of Time Jeane McCarty West Coast Neonatology Todd McCormick JoAnna McKee Green Cross Patient Co-Op Manon McKinnon Empower America George McMahon Peter McWilliams John Edward Mendelson University of California at San Francisco Bonnie Metcalf Yuba County Compassionate Use Co-Op R. Mikin American Academy of Addiction Psychiatry Alan D. Miller The Rockefeller University Jim Montgomery John P. Morgan City University of New York Medical School

OCR for page 229
Page 229 Arlene Munoz Office of Substance Abuse, San Joaquin County Elvy Musikka Richard E. Musty University of Vermont Edgar P. Nace American Academy of Addiction Psychiatry Joyce Nalepka America Cares Tammera Nauts Great Falls Public Schools Dan Noelle Multnomah County Sheriff Stephen O'Brien East Bay Aids Center Jerry Olli Michigan Elks and Michigan Communities in Action for Drug-Free Youth Lynn Osburn Access Unlimited Robert Pandina Rutgers, The State University of New Jersey David Pate HortaPharm B.V. Maggie Petito Drug Watch International Stephen Popolizio The International Association of Lions Clubs Jo Prang NFP Networker (Oregon Partnership) Adolescent Substance Abuse Prevention, Inc. /MEDICAP Pharmacy Beny Primm Addiction Research and Treatment Corporation Carol Reeves Greenville Family Partnership Irvin Rosenfeld Stockbroker Michael Rowbotham University of California at San Francisco A. Kenison Roy American Society of Addiction Reid Rubsamen Aradigm Sue Rusche National Families in Action Clara Sanudo-Pena Brown University Peggy Sapp Informed Families C. Robert Schuster Wayne State University School of Medicine

OCR for page 230
Page 230 Greg Scott Richard Scribner Louisiana State University Medical School Betty S. Sembler S.O.S. Richard W. Sharke McDowell Drug Task Force/ CADCA Lynette Shaw Marin Alliance for Medical Marijuana John Sheridan New York City Marijuana Buyers' Club Cathy Shipp PRIDE-Omaha, Inc. Stephen Sidney Kaiser Permanente Brian Slater Kenneth Smuland Women's Alliance for Medical Marijuana Mark Stone Washington, D.C., Police Department Barb Sweeney Flower Therapy Donald Tashkin University of California at Los Angeles School of Medicine Dana Taub Chuck Thomas Marijuana Policy Project Foundation Bill Tiuen Gainesville Family Partnership Joyce Tobias Parents' Association to Neutralize Drug and Alcohol Abuse, Inc. Jeanne Trumble American Academy of Addiction Psychiatry Barbara Urist-Fenton OCHC Eric A. Voth International Drug Strategy Institute Michelle Voth Kansas Family Partnership C. Gary Wainwright American Civil Liberties Union J. Michael Walker Brown University Gene Weeks Southern California Medical Cannabis Consumers' Co-Op Sandra Welch Medical College of Virginia

OCR for page 231
Page 231 Tracy Wells Family Service-Healthy Alternatives for Little Ones Sgt. Larry L. Welty Oregon State Police Sis Wenger National Association of Children of Alcoholics Lennice Werth Virginians Against Drug Violence Casey Wilbanks Green Cross Carol Wortman Drug Watch Pennsylvania Kevin Zeese Common Sense for Drug Policy

Representative terms from entire chapter:

medical marijuana